Clinical Guidance from Genelex
Reducing Adverse Drug Events, Improving Treatment Outcomes
When it comes to prescribing drugs and evaluating patients for potential drug interactions, pharmacogenetic testing is no longer a future consideration.
- The American Medical Association advocates that physicians become familiar with genetic variations that can affect patients’ drug metabolism, and be able to recognize when testing should be used to inform prescribing.
- The U.S. Food and Drug Administration currently recommends testing in specific instances (to determine the starting dose for warfarin, for example), and is laying the groundwork for routine testing in early phase clinical drug trials.
- A report from the U.S. Department of Health and Human Services states: “Pharmacogenetic testing for potential adverse drug events (ADEs) or ineffective drug responses may reduce health care costs over the long term by diminishing the duration and severity of illness and the costs associated with ineffective treatment and avoidable ADEs.”
Genelex DNA pharmacogenetic testing powered by YouScript is the alternative to “one size fits all” drug prescribing that can lead to potentially serious side effects, treatment failure, and poor patient compliance. Pharmacogenetic testing combined with the YouScript Precision Prescribing Software reveals drug-metabolizing gene variants—found in more than one-half of patients—to help physicians and pharmacists determine the appropriateness and dosage of commonly prescribed drugs such as beta blockers, opioid analgesics, and warfarin.